Table 3. The various published single institution reports of outcomes and toxicity using intensity-modulated radiotherapy for radiation delivery in nasopharyngeal cancers.
| Author | Patients, n | Stage | CRT | LRC | OS | Incidence >grade 2 xerostomia (late) |
| Sultanem et al [19] | 35 | I–IV | 91% | 100% (4 years) | 94% (4 years) | 0% |
| Lee et al [88] | 67 | I–IV | 74% | 98% (4 years) | 88% (4 years) | 0.3% |
| Kam et al [89] | 63 | I–IV | 30% | 92% (3 years) | 90% (3 years) | 23% |
| Wolden et al [90] | 74 | I–IV | 93% | 91% (3 years) | 83% (3 years) | 32% |
| Lai et al [91] | 512 | I–IV | 82% | 93% (5 years) | 76% (5 years) | NR |
| Han et al [92] | 305 | I–IV | 85% | 98% (3 years) | 89% (3 years) | 7% |
| Lin S [93] | 323 | II–IV | 90% | 98% (3 years) | 90% (3 years) | 8% |
CRT, concomitant radiotherapy; LRC, locoregional control; NR, not reported; OS, overall survival.